Type I interferon pathway genetic variants in severe COVID-19

被引：4
作者：
Montenegro, A. F. L. [1 ]
Clementino, M. A. F. [2 ]
Yaochite, J. N. U. [1 ]
机构：
[1] Univ Fed Ceara UFC, Fac Farm Odontol & Enfermagem, Dept Anal Clin & Toxicol, Lab Imunol Celular & Mol, Rua Pastor Samuel Munguba 1210, Fortaleza, Ceara, Brazil
[2] Univ Fed Ceara UFC, Lab Toxinol Mol, NUBIMED Nucleo Biomed, Fortaleza, Ceara, Brazil
来源：
VIRUS RESEARCH | 2024年 / 342卷
关键词：
COVID-19; Type I interferon; Single nucleotide polymorphisms; SUSCEPTIBILITY; IMMUNITY; INNATE;
D O I：
10.1016/j.virusres.2024.199339
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. According to the World Health Organization (WHO), there have been over 760 million reported cases and over 6 million deaths caused by this disease worldwide. The severity of COVID-19 is based on symptoms presented by the patient and is divided as asymptomatic, mild, moderate, severe, and critical. The manifestations are interconnected with genetic variations. The innate immunity is the quickest response mechanism of an organism against viruses. Type I interferon pathway plays a key role in antiviral responses due to viral replication inhibition in infected cells and adaptive immunity stimulation induced by interferon molecules. Thus, variants in type I interferon pathway's genes are being studied in different COVID-19 manifestations. This review summarizes the role of variants in type I interferon pathway's genes on prognosis and severity progression of COVID-19.
引用
收藏
页数：9
相关论文
共 84 条
[61]   COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types [J].
Schmiedel, Benjamin J. ;
Chandra, Vivek ;
Rocha, Job ;
Gonzalez-Colin, Cristian ;
Bhattacharyya, Sourya ;
Madrigal, Ariel ;
Ottensmeier, Christian H. ;
Ay, Ferhat ;
Vijayanand, Pandurangan .
NATURE COMMUNICATIONS, 2021, 12 (01)
[62]   Interferon-Stimulated Genes: What Do They All Do? [J].
Schoggins, John W. .
ANNUAL REVIEW OF VIROLOGY, VOL 6, 2019, 2019, 6 :567-584
[63]   The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 [J].
Schreiber, Gideon .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[64]   The molecular basis for differential type I interferon signaling [J].
Schreiber, Gideon .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (18) :7285-7294
[65]   Lots of long COVID treatment leads, but few are proven [J].
Shaffer, Leah .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (36)
[66]   Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past [J].
Shah, Vibhuti Kumar ;
Firmal, Priyanka ;
Alam, Aftab ;
Ganguly, Dipyaman ;
Chattopadhyay, Samit .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[67]  
Shastry B.S, 2009, Single Nucleotide Polymorphisms: Methods & Protocols, P1, DOI [10.1007/978-1-60327-411-1, DOI 10.1007/978-1-60327-411-1]
[68]   Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity [J].
Smith, Nikaia ;
Posseme, Celine ;
Bondet, Vincent ;
Sugrue, Jamie ;
Townsend, Liam ;
Charbit, Bruno ;
Rouilly, Vincent ;
Saint-Andre, Violaine ;
Dott, Tom ;
Pozo, Andre Rodriguez ;
Yatim, Nader ;
Schwartz, Olivier ;
Cervantes-Gonzalez, Minerva ;
Ghosn, Jade ;
Bastard, Paul ;
Casanova, Jean Laurent ;
Szwebel, Tali-Anne ;
Terrier, Benjamin ;
Conlon, Niall ;
O'Farrelly, Cliona ;
Cheallaigh, Cliona Ni ;
Bourke, Nollaig M. ;
Duffy, Darragh .
NATURE COMMUNICATIONS, 2022, 13 (01)
[69]   Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection [J].
Solimani, Farzan ;
Meier, Katharina ;
Ghoreschi, Kamran .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (05) :1071-1075
[70]   Serum levels of type I interferon (IFN-I) is associated with the severity of COVID-19 [J].
Sun, Yuting ;
Wang, Gang ;
Wang, Rongshuai ;
Ren, Liang ;
Yuan, Zilin ;
Liu, Yueping ;
Wu, Yuzhang ;
Chen, Rong ;
Chen, Yongwen ;
Diao, Bo .
JOURNAL OF MEDICAL MICROBIOLOGY, 2023, 72 (08)
123456789